MicroRNAs in bipolar disorder: Diagnostic and therapeutic applications;MicroARN en el trastorno bipolar: Posibles aplicaciones diagnósticas y terapéuticas

Revista de Neurologia

Volumn 53, Issue 2, 2011, Pages 91-98

  Suárez Gómez, María ^a,b   Alejandre Durán, Encarna ^b   Ruiz Rubio, Manuel ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Bipolar disorder; Genetics; Lithium; MicroRNA; MiRNA; Valproate

Indexed keywords

LITHIUM; MICRORNA; VALPROIC ACID;

BIPOLAR DISORDER; DISEASE PREDISPOSITION; HUMAN; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 79960684150     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5302.2010661     Document Type: Review

References (60)

1. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990.
2. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59 (Suppl 1): S5-30.
3. Beers CW. A mind that found itself: an autobiography. Garden City, NY: Doubleday; 1953.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV, 4th ed. Washington DC: APA; 1994.
5. Akiskal HS, Benazzi F. The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord 2006; 92: 45-54.
6. Alaerts M, Del Favero J. Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future. Hum Mutat 2009; 30: 1139-52.
7. Pies R. Have we undersold lithium for bipolar disorder? J Clin Psychopharmacol 2002; 22: 445-9.
8. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002; 63 (Suppl 10): S5-12.
9. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000; 26: 13-25.
10. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-82.
11. Belmaker RH, Agam G. Bipolar disorder: neurochemistry and drug mechanisms. Discovery Medicine 2005; 5: 191-8.
12. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164: 331-43.
13. Schulze TG. Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. Psychiatr Clin North Am 2010; 33: 67-82.
14. McQueen MB, Devlin B, Faraone SV, Nimgaonkar VL, Sklar P, Smoller JW, et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005; 77: 582-95.
15. Serretti A, Mandelli L. The genetics of bipolar disorder: genome 'hot regions' genes, new potential candidates and future directions. Mol Psychiatry 2008; 13: 742-71.
16. Hayden EP, Nurnberger JI Jr. Molecular genetics of bipolar disorder. Genes Brain Behav 2006; 5: 85-95.
17. Dallaspezia S, Benedetti F. Melatonin, circadian rhythms, and the clock genes in bipolar disorder. Curr Psychiatry Rep 2009; 11: 488-93.
18. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197-207.
19. Le-Niculescu H, Patel SD, Niculescu AB. Convergent integration of animal model and human studies of bipolar disorder (manic-depressive illness). Curr Opin Pharmacol 2010; 10: 594-600.
20. Baum AE, Hamshere M, Green E, Cichon S, Rietschel M, Noethen MM, et al. Meta-analysis of two genome-wide association studies of bipolar disorder reveals important points of agreement. Mol Psychiatry 2008; 13: 466-7.
21. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-8.
22. Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, Condie A, et al. Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol Psychiatry 2005; 10: 657-68.
23. Chen X, Li X, Wang P, Liu Y, Zhang Z, Zhao G, et al. Novel association strategy with copy number variation for identifying new risk Loci of human diseases. PloS One 2010; 5: 1-10.
24. Zhang D, Cheng L, Qian Y, Alliey-Rodríguez N, Kelsoe JR, Greenwood T, et al. Singleton deletions throughout the genome increase risk of bipolar disorder. Mol Psychiatry 2009; 14: 376-80.
25. Ansorge WJ. Next-generation DNA sequencing techniques. N Biotechnol 2009; 25: 195-203.
26. Burmeister M, McInnis MG, Zollner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet 2008; 9: 527-40.
27. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355-67.
28. Keverne EB, Fundele R, Narasimha M, Barton SC, Surani MA. Genomic imprinting and the differential roles of parental genomes in brain development. Brain Res Dev Brain Res 1996; 92: 91-100.
29. Gregg C, Zhang J, Weissbourd B, Luo S, Schroth GP, Haig D, et al. High-resolution analysis of parent-of-origin allelic expression in the mouse brain. Science 2010; 329: 643-8.
30. Miller BH, Wahlestedt C. MicroRNA dysregulation in psychiatric disease. Brain Res 2010; 1338: 89-99.
31. Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008; 9: 831-42.
32. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
33. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
34. Valencia-Sánchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515-24.
35. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
36. Kuss AW, Chen W. MicroRNAs in brain function and disease. Curr Neurol Neurosci Rep 2008; 8: 190-7.
37. Muljo SA, Kanellopoulou C, Aravind L. MicroRNA targeting in mammalian genomes: genes and mechanisms. Wiley Interdisciplinary Reviews 2010; 2: 148-61.
38. Kosik KS. The neuronal microRNA system. Nat Rev Neurosci 2006; 7: 911-20.
39. Heneghan HM, Miller N, Kerin MJ. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010; 28: 573-4.
40. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32: 189-94.
41. Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 2010; 119: 395-405.
42. Brea D, Blanco M, Sobrino T, Ramos-Cabrer P, Castillo J. Los niveles de expresión de los receptores toll-like 2 y 4 en neutrófilos se asocian con el pronóstico de los pacientes con ictus isquémico. Rev Neurol 2011; 52: 12-9.
43. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310: 317-20.
44. Fiore R, Siegel G, Schratt G. MicroRNA function in neuronal development, plasticity and disease. Biochim Biophys Acta 2008; 1779: 471-8.
45. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004; 5: 13.
46. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183-91.
47. Cao X, Yeo G, Muotri AR, Kuwabara T, Gage FH. Noncoding RNAs in the mammalian central nervous system. Annu Rev Neurosci 2006; 29: 77-103.
48. Schratt G. MicroRNAs at the synapse. Nat Rev Neurosci 2009; 10: 842-9.
49. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini, ME, Kiebler M, et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006; 439: 283-9.
50. Lin YC, Koleske AJ. Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders. Annu Rev Neurosci 2010; 33: 349-78.
51. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, et al. MicroRNA modulation of circadian-clock period and entrainment. Neuron 2007; 54: 813-29.
52. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009; 34: 1395-405.
53. Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 2010; 45: 92-5.
54. Navarrete F, Pérez-Ortiz JM, Femenía T, García-Gutiérrez MS, García-Payá ME, Leiva-Santana C, et al. Métodos de evaluación de trastornos cognitivos en modelos animales. Rev Neurol 2008; 47: 137-45.
55. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010; 65: 373-84.
56. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004; 7: 113-7.
57. Tanizawa Y, Kuhara A, Inada H, Kodama E, Mizuno T, Mori I. Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev 2006; 20: 3296-310.
58. Tokuoka SM, Saiardi A, Nurrish SJ. The mood stabilizer valproate inhibits both inositol-and diacylglycerol-signaling pathways in Caenorhabditis elegans. Mol Biol Cell 2008; 19: 2241-50.
59. Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 110-33.
60. Boudreau RL, Davidson BL. RNAi therapeutics for CNS disorders. Brain Res 2010; 1338: 112-21.